As an example, YKL-40 can be upregulated by proinflammatory cytokines, including tumor necrosis factor-α, which is a potential therapeutic target for patients affected by rheumatoid arthritis (RA). This evidence concerns the gene CHI3L1 and rheumatoid arthritis.